Ongoing Rhythm RM-718 trial: two mild pigmentation cases at injection sites
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported preliminary Phase 2 open-label data for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. Eleven patients were enrolled; among 7 assessed at Week 16, mean BMI fell 11.6% from baseline. The company cited similar BMI declines to bivamelagon and setmelanotide and reported limited mild injection-site hyperpigmentation. Two patients discontinued due to adverse events.
How this was made
The 30-second read
Why it matters
The disclosed preliminary Phase 2 results provide a fresh efficacy and safety snapshot for RM-718, with BMI reduction at Week 16 and hyperpigmentation limited to injection sites. This can shift near-term expectations for the program, but the small sample size and open-label nature reduce statistical confidence.
Market read
Traders may reprice RM-718 development prospects based on the magnitude of BMI reduction and the apparent localization of hyperpigmentation, ahead of the company’s same-day call.
What to watch
Two discontinuations due to adverse events and one withdrawal from the extension portion suggest tolerability and retention risks; also, the article does not provide durability beyond 16 weeks or any biomarker/functional endpoints.
Background
Rhythm is a commercial-stage biopharma with setmelanotide (IMCIVREE) approved for acquired hypothalamic obesity and certain genetic obesity indications; RM-718 is an investigational once-weekly MC4R agonist designed to be MC1R-sparing to reduce hyperpigmentation risk.
Ticker impact
Rhythm reported preliminary Phase 2 RM-718 data in acquired hypothalamic obesity, including -11.6% mean BMI at Week 16 (n=7) and limited injection-site hyperpigmentation.
Near-term sentiment likely positive, with volatility around the same-day call and any incremental Q2 business updates; follow-through depends on later, larger datasets and durability.
The article discloses fresh preliminary clinical datapoints (BMI change, discontinuations, hyperpigmentation localization) and a same-day investor call, but efficacy is based on only seven patients at Week 16 and lacks controlled comparisons.
Market effects
Reinforces competitive narrative in MC4R-pathway obesity drugs, potentially affecting sentiment toward other rare-obesity/MC4R agonist development programs.
Primarily US-focused sentiment for Nasdaq-listed Rhythm; limited direct spillover implied.
Could modestly influence global rare-obesity investor sentiment if the hyperpigmentation profile is viewed as differentiating, but no regulatory or label expansion is disclosed here.
Counterpoint
The efficacy signal may not hold in a larger, controlled cohort; the Week 16 analysis is based on only seven evaluated patients and open-label bias could overstate effect size.
Key entities
- companyRhythm Pharmaceuticals
Nasdaq-listed company reporting preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity.
- assetRM-718
Investigational once-weekly MC4R agonist in an open-label Phase 2 trial for acquired hypothalamic obesity.
- productIMCIVREE (setmelanotide)
Approved MC4R agonist used as a comparator for BMI reduction magnitude in the company’s discussion.
